Vasculogenic mimicry, a complex and devious process favoring tumorigenesis -Interest in making it a therapeutic target - Archive ouverte HAL Access content directly
Journal Articles Pharmacology & Therapeutics Part A Chemotherapy Toxicology and Metabolic Inhibitors Year : 2021

Vasculogenic mimicry, a complex and devious process favoring tumorigenesis -Interest in making it a therapeutic target

(1) , (2) , (2)
1
2

Abstract

Tumor cell vasculogenic mimicry (VM), also dubbed vascular mimicry, describes the plasticity of aggressive cancer cells forming de novo vascular networks and is associated with the malignant phenotype and poor clinical outcome. VM is described in a plethora of tumors, including carcinomas, sarcomas, glioblastomas, astrocytomas and melanomas. The presence of VM is associated with a high tumor grade, short survival, invasion and metastasis. A variety of molecular mechanisms and signal pathways participates in VM induction and formation. Due to VM's contribution on tumor progression, more VM-related strategies are being utilized for anticancer treatment. After describing the main features of VM, this review will outline the importance of the tumor microenvironment during this process, and highlight the predominant molecular targets and signaling pathways involved. These data will make it possible to discuss the importance of VM-associated mediators in antitumor therapy and how it could allow to better understand the resistance to anticancer therapy.
Fichier principal
Vignette du fichier
Treps2021Eq04.pdf (4.59 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-03349934 , version 1 (21-09-2021)

Identifiers

Cite

Lucas Treps, Sébastien Faure, Nicolas Clere. Vasculogenic mimicry, a complex and devious process favoring tumorigenesis -Interest in making it a therapeutic target. Pharmacology & Therapeutics Part A Chemotherapy Toxicology and Metabolic Inhibitors, 2021, 223, pp.107805. ⟨10.1016/j.pharmthera.2021.107805⟩. ⟨inserm-03349934⟩
163 View
116 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More